
Contents

1	Designs and Strategies for Genomic Mapping and Haplotyping	1
1.1	Fundamental Genetics	1
1.1.1	Chromosomes and Map	1
1.1.2	Genotype and Phenotype	2
1.1.3	Molecular Genetic Markers	3
1.1.4	The HapMap	4
1.2	Pharmacogenetics and Pharmacogenomics	5
1.3	Genetic Designs	8
1.3.1	Experimental Crosses	8
1.3.2	Nuclear Families	9
1.3.3	Natural Populations with Unrelated Individuals	9
1.3.4	Natural Populations with Unrelated Families	10
1.4	Strategies for Genomic Mapping	11
1.4.1	Linkage Mapping	11
1.4.2	Linkage Disequilibrium Mapping	13
1.4.3	Joint Linkage and Linkage Disequilibrium Mapping	15
1.5	From QTL to QTN	16
1.5.1	Genotype and Diplotype	17
1.5.2	Identification of QTNs	18
1.6	Functional Mapping of Drug Response	19
2	Genetic Haplotyping in Natural Populations	21
2.1	Notation and Definitions	21
2.2	Likelihoods	23
2.3	The EM Algorithm	24
2.4	Sampling Variances of Parameter Estimates	25
2.5	Model Selection	27
2.6	Hypothesis Tests	28
2.7	Haplotyping with Multiple SNPs	29
2.7.1	Haplotype Structure	29
2.7.2	Likelihoods and Algorithms	31
2.8	R-SNP Model	35

3	Genetic Haplotyping in Experimental Crosses	39
3.1	LD Analysis in the F_1 's Gamete Population	40
3.1.1	A General Model	40
3.1.2	A Special Case: Two-Point LD	41
3.1.3	A Special Case: Three-Point LD	41
3.2	LD Analysis in the Backcross	43
3.2.1	Design	43
3.2.2	Analysis of Variance	44
3.2.3	t -Test	44
3.3	LD Analysis in the F_2	47
3.3.1	Mixture Model	47
3.3.2	Likelihoods, Estimation, and Hypothesis Tests	48
3.3.3	Model Selection: Two- vs. Three-Point LD Analysis	48
3.4	LD Analysis in a Full-Sib Family	51
3.4.1	Introduction	51
3.4.2	A General Model	52
3.4.3	Estimation	53
3.4.4	Multiple Segregating Types of Markers	56
3.4.5	Three-Point Haplotyping	57
3.5	Prospects	58
4	A General Quantitative Model for Genetic Haplotyping	61
4.1	Quantitative Genetic Models	62
4.1.1	Population Structure	62
4.1.2	Biallelic Model	62
4.1.3	Triallelic Model	63
4.1.4	Quadriallelic Model	64
4.2	Likelihood	65
4.2.1	The EM Algorithm	67
4.2.2	Model Selection	67
4.2.3	Hypothesis Tests	67
4.3	Three-SNP Haplotyping	68
4.4	Haplotyping in a Non-Equilibrium Population	70
4.5	Prospects	73
5	Basic Principle of Functional Mapping	75
5.1	Dynamic Genetic Control	76
5.2	Structure of Functional Mapping	77
5.2.1	Mixture Model	78
5.2.2	Modeling the Mean-Covariance Structure	79
5.3	Estimation of Functional Mapping	82
5.3.1	Likelihood	82
5.3.2	Algorithm	83
5.4	Hypothesis Tests of Functional Mapping	84
5.5	Transform-Both-Sides Model of Functional Mapping	88

5.6	Structured Antedependence Model of Functional Mapping	90
5.6.1	Antedependence Model	90
5.6.2	Structured Antedependence Model	90
5.6.3	Model Selection	91
5.7	An Optimal Strategy of Structuring the Covariance	91
5.7.1	Standard Deviation Function	92
5.7.2	Correlation Function	92
5.7.3	Model Selection	93
5.8	Functional Mapping Meets Ontology	94
6	Functional Mapping of Pharmacokinetics and Pharmacodynamics	97
6.1	Mathematical Modeling of Pharmacokinetics and Pharmacodynam- ics	98
6.1.1	Modeling Pharmacokinetics	98
6.1.2	Modeling Pharmacodynamics	98
6.1.3	Linking Pharmacokinetics and Pharmacodynamics	100
6.2	Functional Mapping of Pharmacokinetics	101
6.2.1	Kinetic Derivation of a Bi-Exponential Model	102
6.2.2	QTL Mapping with a Bi-Exponential Model	104
6.2.3	Functional Mapping Based on Ho et al.'s Kinetic Model	112
6.3	Functional Mapping of Pharmacodynamics	114
6.3.1	Patterns of Genetic Control in Pharmacodynamics	114
6.4	Sequencing Pharmacodynamics	115
6.4.1	Basic Model	115
6.4.2	A Pharmacogenetic Study of Heart Rate Responses	117
7	Haplotyping Drug Response by Linking Pharmacokinetics and Pharma- codynamics	123
7.1	A Unifying Model for Functional Mapping	123
7.1.1	Clinical Design	123
7.1.2	Likelihood	124
7.1.3	Modeling the Mean Vector	128
7.1.4	Modeling the Covariance Structure	128
7.2	Algorithms and Determination of Risk Haplotypes	133
7.3	Hypothesis Tests	133
7.4	Computer Simulation	135
7.5	Genetic and Statistical Considerations	138
8	Functional Mapping of Biological Clocks	141
8.1	Mathematical Modeling of Circadian Rhythms	142
8.2	Haplotyping Circadian Rhythms	143
8.2.1	Study Design	143
8.2.2	Antedependence Model	144
8.2.3	Likelihood	146
8.2.4	Algorithm and Determination of Risk Haplotypes	147

8.3	Hypothesis Testing	148
8.3.1	Existence of Risk Haplotypes	148
8.3.2	Pleiotropic Effect on mRNA or Protein Rhythms	149
8.3.3	Risk Haplotypes for the Behavior and Shape of Circadian Rhythms	149
8.4	Simulation	150
8.5	Fourier Series Approximation of Circadian Rhythms	150
8.5.1	Introduction	150
8.5.2	Fourier Model	151
8.5.3	Genetic Haplotyping	153
8.6	Further Considerations	156
9	Genetic Mapping of Allometric Scaling	159
9.1	Allometric Models	159
9.2	Allometric Mapping	161
9.2.1	Genetic Design	161
9.2.2	Likelihood and Estimation	162
9.3	Hypothesis Testing	164
9.4	Allometric Mapping with a Pleiotropic Model	165
9.4.1	Design	165
9.4.2	Genetic Model	165
9.4.3	Statistical Estimation	167
9.4.4	Hypothesis Tests	167
9.5	Allometric Mapping with General Power Equations	168
9.5.1	Estimating Power Coefficients Using Model II Non-Linear Regression	168
9.5.2	Predicting Dependent Variables	170
10	Functional Mapping of Drug Response with Allometric Scaling	175
10.1	Allometric Scaling of Pharmacokinetic and Pharmacodynamic Responses	176
10.2	Model Derivations	177
10.2.1	Experimental Design	177
10.2.2	Model Structure and Estimation	178
10.2.3	Hypothesis Testing	179
10.3	A Pleiotropic Model for Allometric Mapping	184
10.4	Genetic Haplotyping with Developmental Allometry	184
10.4.1	Likelihood	185
10.4.2	Algorithm	187
10.4.3	Hypothesis Testing	189
11	Joint Functional Mapping of Drug Efficacy and Toxicity	195
11.1	A Joint Model	196
11.1.1	Genetic Design	196
11.1.2	Clinical Design	197

11.1.3	Statistical Design	198
11.1.4	The Haplotyping Framework	198
11.1.5	Covariance Structure	201
11.1.6	Algorithm and Determination of Risk Haplotypes	203
11.2	Hypothesis Testing	203
11.2.1	Existence of Risk Haplotypes	204
11.2.2	Different Risk Haplotypes for PK and PD	204
11.2.3	Different Risk Haplotypes for Drug Efficacy and Drug Toxicity	205
11.2.4	Risk Haplotypes Responsible for Individual Curve Parameters	206
11.3	Closed Forms for the SAD Structure	210
11.4	Allometric Mapping of Drug Efficacy and Drug Toxicity	211

12 Modeling Epistatic Interactions in Drug Response 213

12.1	Quantitative Genetic Models for Epistasis	214
12.1.1	Definition and Type	214
12.1.2	Quantifying Epistasis	215
12.1.3	From Static to Dynamic	216
12.2	Haplotyping Epistasis	217
12.2.1	Population Genetic Structure	217
12.2.2	Genetic Design	218
12.2.3	Population Genetic Model	219
12.2.4	Likelihood for Estimating Across-Block Haplotype Frequencies	219
12.2.5	Likelihood for Haplotype-Haplotype Interaction Effects	226
12.2.6	Hypothesis Tests	228
12.3	Haplotyping Epistasis of Drug Response	233
12.3.1	Introduction	233
12.3.2	Model and Estimation	233
12.3.3	Hypothesis Tests	235
12.4	Prospects	243

13 Mapping Genotype-Environment Interactions in Drug Response 245

13.1	Haplotyping Genotype-Environment Interactions	246
13.1.1	Environmental Sensitivity and Genotype-Environment Interactions	246
13.1.2	Genetic Design	248
13.1.3	Likelihoods	249
13.1.4	The EM Algorithm	252
13.1.5	Model Selection	252
13.1.6	Hypothesis Tests	252
13.1.7	Haplotyping with Multiple SNPs	255
13.2	Haplotyping Genotype-Environment Interactions for Pharmacological Processes	259

13.2.1	Introduction	259
13.2.2	Dynamic Model	261
13.2.3	Hypothesis Testing	262
13.3	Genetic Considerations	268
14	Nonparametric Functional Mapping of Drug Response	271
14.1	Nonparametric Modeling with Legendre Polynomial	272
14.1.1	Legendre Orthogonal Polynomials	272
14.1.2	Genetic Design	273
14.1.3	Likelihoods	275
14.1.4	Model Selection	276
14.1.5	Hypothesis Tests	277
14.2	Nonparametric Modeling of Event Processes with Legendre Poly- nomial	278
14.2.1	Introduction	278
14.2.2	Model and Estimation	278
14.2.3	Hypothesis Testing	280
14.3	Nonparametric Functional Mapping with B-Spline	282
14.3.1	Basics of B-Splines	282
14.3.2	Haplotyping Model for DNA Sequence Variants	285
14.4	Nonparametric Functional Mapping of Pharmacokinetics and Phar- macodynamics	285
14.5	Nonparametric Modeling of the Covariance Structure	286
15	Semiparametric Functional Mapping of Drug Response	287
15.1	Problems	288
15.1.1	Long-Term HIV Dynamics	288
15.1.2	Different Phases of Programmed Cell Death	290
15.2	Semiparametric Modeling of Functional Mapping: HIV Dynamics	291
15.2.1	Genetic Design	291
15.2.2	Model Structure	292
15.2.3	Model Estimation	296
15.2.4	Hypothesis Testing	297
15.3	Semiparametric Modeling of Functional Mapping: PCD	299
15.3.1	Phase Dissection of Growth	299
15.3.2	Haplotyping Model	302
15.3.3	Computation Algorithms	303
15.3.4	Hypothesis Testing	304
	References	309
	Author Index	333
	Subject Index	341